Michael Barbella, Managing Editor05.16.23
Establishment Labs Holdings Inc. has entered into agreements with four partners in Europe and a second partner chain in Japan for Mia Femtech (Mia).
“Our global rollout of Mia Femtech continues, and we are pleased to announce our first European partners in Sweden, Switzerland, and Spain, as well as an additional chain in Japan,” Establishment Labs Founder/CEO Juan José Chacón-Quirós said. “We expect to partner with many more centers with a focus on creating premium experiences with broad appeal. Mia is opening breast aesthetics to a new group of consumers and the strong interest in partnering with us demonstrates the potential of Mia to dramatically expand our markets. We look forward to many more announcements on Mia over the coming months.”
In Stockholm, Sweden, Establishment Labs is partnering with Nordiska Kliniken, a Scandinavian clinic specializing in plastic surgery and aesthetic treatments. In Switzerland, the company is working with Leman Aesthetic Clinic in Geneva and Clinic Utoquai in Zurich, which are both internationally recognized and well-established in aesthetics. “As leaders in plastic surgery, we are proud to introduce Mia Femtech as the coming evolution in breast aesthetics. Building Nordiska Kliniken has always been about innovating and this is the next natural step in our journey of being market leaders,” Nordiska Kliniken CEO Sam Besara said.
In Barcelona, Spain, Clínica Planas is known as a provider of premium services and outcomes in plastic surgery. Joe Clinic is a high-end medical aesthetics chain in Japan that will begin initially by offering Mia at its Tokyo and Osaka locations.
“Mia Femtech will define a new premium aesthetic category with great potential for expanding the market,” Clinica Planas CEO Javier Planas stated. “Clínica Planas has been a pioneer in aesthetics since 1971, and we are excited to once again be at the forefront of innovation and excellence.”
Mia Femtech is Establishment Labs’ breakthrough minimally invasive breast aesthetics experience. The patented technologies used with Mia can shape the breast up one to two cups in a 15-minute procedure without the need for general anesthesia.
Mia Femtech is not yet commercially available in the European Union and the United States.
Establishment Labs Holdings Inc. is a global medical technology company offering a portfolio of Femtech solutions for breast health, breast aesthetics, and breast reconstruction. The more than 2.5 million Motiva devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the over 85 countries in which they are available. The Motiva Flora tissue expander is the only regulatory-approved expander in the world with an integrated port that is MRI conditional and is used to improve outcomes in breast reconstruction following breast cancer. Mia Femtech, Establishment Lab’s unique minimally invasive experience for breast harmony, is the company’s most recent innovation. These solutions are supported by more than 200 patent applications in 25 separate patent families worldwide and more than 50 scientific studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2016 and U.S. Food and Drug Administration (FDA) 21 CFR 820 under the MDSAP program. In 2018, the company received an investigational device exemption (IDE) from the FDA for Motiva Implants and began a clinical trial to support regulatory approval in the United States.
Read more: Japanese Regulators Approve Motiva Implants, Tissue Expander
“Our global rollout of Mia Femtech continues, and we are pleased to announce our first European partners in Sweden, Switzerland, and Spain, as well as an additional chain in Japan,” Establishment Labs Founder/CEO Juan José Chacón-Quirós said. “We expect to partner with many more centers with a focus on creating premium experiences with broad appeal. Mia is opening breast aesthetics to a new group of consumers and the strong interest in partnering with us demonstrates the potential of Mia to dramatically expand our markets. We look forward to many more announcements on Mia over the coming months.”
In Stockholm, Sweden, Establishment Labs is partnering with Nordiska Kliniken, a Scandinavian clinic specializing in plastic surgery and aesthetic treatments. In Switzerland, the company is working with Leman Aesthetic Clinic in Geneva and Clinic Utoquai in Zurich, which are both internationally recognized and well-established in aesthetics. “As leaders in plastic surgery, we are proud to introduce Mia Femtech as the coming evolution in breast aesthetics. Building Nordiska Kliniken has always been about innovating and this is the next natural step in our journey of being market leaders,” Nordiska Kliniken CEO Sam Besara said.
In Barcelona, Spain, Clínica Planas is known as a provider of premium services and outcomes in plastic surgery. Joe Clinic is a high-end medical aesthetics chain in Japan that will begin initially by offering Mia at its Tokyo and Osaka locations.
“Mia Femtech will define a new premium aesthetic category with great potential for expanding the market,” Clinica Planas CEO Javier Planas stated. “Clínica Planas has been a pioneer in aesthetics since 1971, and we are excited to once again be at the forefront of innovation and excellence.”
Mia Femtech is Establishment Labs’ breakthrough minimally invasive breast aesthetics experience. The patented technologies used with Mia can shape the breast up one to two cups in a 15-minute procedure without the need for general anesthesia.
Mia Femtech is not yet commercially available in the European Union and the United States.
Establishment Labs Holdings Inc. is a global medical technology company offering a portfolio of Femtech solutions for breast health, breast aesthetics, and breast reconstruction. The more than 2.5 million Motiva devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the over 85 countries in which they are available. The Motiva Flora tissue expander is the only regulatory-approved expander in the world with an integrated port that is MRI conditional and is used to improve outcomes in breast reconstruction following breast cancer. Mia Femtech, Establishment Lab’s unique minimally invasive experience for breast harmony, is the company’s most recent innovation. These solutions are supported by more than 200 patent applications in 25 separate patent families worldwide and more than 50 scientific studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2016 and U.S. Food and Drug Administration (FDA) 21 CFR 820 under the MDSAP program. In 2018, the company received an investigational device exemption (IDE) from the FDA for Motiva Implants and began a clinical trial to support regulatory approval in the United States.
Read more: Japanese Regulators Approve Motiva Implants, Tissue Expander